Table 9.
Predictors of stocking of DHAPQ-ACT by PPMVs
| Variables | Dihydroartemisinin (DHAPQ) in yes n (%) | Piperaquine stock no n (%) | X2 (p-value) | OR (95% CI) |
|---|---|---|---|---|
| Health-related qualification | ||||
| No health qualification (ref) | 14 (4.6) | 292 (95.4) | ||
| Has health qualification | 3 (21.4) | 11 (78.6) | 7.56 (0.006)* | 5.69 (1.42–22.72) |
| Manufacturer as the source of purchase of anti-malarial | ||||
| No (ref) | 16 (5.1) | 300 (94.9) | ||
| Yes | 1 (25.0) | 3 (75.0) | 3.12 (0.077) | 6.25 (0.62–63.49) |
| Sales representatives as a source of information on government recommended anti-malarial medication | ||||
| No (ref) | 14 (4.6) | 289 (95.4) | ||
| Yes | 3 (17.6) | 14 (82.4) | 5.43 (0.020)* | 4.42 (1.14–17.19) |
| PPMV knew the national recommended guideline for malaria diagnosis | ||||
| Incorrect knowledge (ref) | 15 (4.8) | 297 (95.2) | ||
| Correct knowledge | 2 (25.0) | 6 (75.0) | 6.32 (0.012)* | 6.60 (1.23–35.49) |
| PPMV used malaria diagnostic tool | ||||
| No (ref) | 14 (4.7) | 286 (95.3) | ||
| Yes | 3 (15.0) | 17 (85.0) | 3.98 (0.046) | 3.61 (0.94–13.76) |
Ref reference category
* Significant p-value